Clinical trials: Treatment Resistant
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Prostate Cancer
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
- Trial name
- ARMOR2 (NCT01709734)
- Testing
- galeterone
- Where
- 23 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Polycystic Ovary Syndrome
Combination of D-chiro-inositol With Ketogenic Diet
The study aims to evaluate whether the combination of a product based on D-chiro-inositol and the ketogenic diet can improve the metabolic/endocrine picture of overweight/obese women with PCOS, with insulin resistance, in a…
- Trial name
- NCT05348967
- Testing
- TECADRIOL
- Where
- Italy
- Sponsor
- Lo.Li.Pharma s.r.l
Serious Bacterial Infection
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI)…
- Trial name
- NCT03580044
- Testing
- ATM-AVI, BAT
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 15 people
- Sponsor
- Pfizer
Treatment-Resistant Depression
Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.
- Trial name
- NCT03312894
- Testing
- TAK-653
- Sponsor
- Millennium Pharmaceuticals, Inc.
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Prostate Cancer
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies.
- Trial name
- NCT07543055
- Testing
- BPX-601
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity signals of MSC2363318A.
- Trial name
- NCT01971515
- Testing
- MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
- Where
- 15 sites in United States
- Volunteers
- 101 people
- Sponsor
- EMD Serono
Depression
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
- Trial name
- NCT01114698
- Testing
- Venlafaxine XR, JNJ26489112
- Where
- 14 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients.
- Trial name
- NCT00615563
- Testing
- NO BI Drug administered
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Prostatic Neoplasms, Castration-Resistant
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Trial name
- SECuRE (NCT04868604)
- Testing
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Platinum-resistant Ovarian Cancer
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are…
- Trial name
- RAINFOL-02 (NCT06619236)
- Testing
- Rina-S, Paclitaxel, Topotecan
- Where
- 177 sites in United States, Australia and 16 more
- Volunteers
- 584 people
- Sponsor
- Genmab
Infections, Nosocomial
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
- Trial name
- NCT00150332
- Testing
- linezolid
- Where
- 20 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Crohn's Disease
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body…
- Trial name
- NCT00482092
- Testing
- Prochymal®
- Where
- 56 sites in United States, Australia and 2 more
- Volunteers
- 330 people
- Sponsor
- Mesoblast, Inc.
Ovarian Cancer
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
- Trial name
- FAR-122 (NCT00738699)
- Testing
- MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
- Where
- 61 sites in United States, Australia and 4 more
- Volunteers
- 415 people
- Sponsor
- Morphotek
Prostate Cancer Metastatic
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to…
- Trial name
- NCT04603833
- Testing
- SHR3680+Docetaxel, SHR3680, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Wound Infection
Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients
The central aim of this trial is to investigate the safety and tolerability of Phage Cocktail-SPK as an adjunct to standard therapy for the prevention and treatment of burns susceptible to infection/or infected by S. aureus, P.
- Trial name
- NCT04323475
- Testing
- Bacteriophage cocktail spray, Xeroform
- Volunteers
- 12 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.